These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
86. Cathepsin-facilitated invasion of BMI1-high hepatocellular carcinoma cells drives bile duct tumor thrombi formation. Xu LB; Qin YF; Su L; Huang C; Xu Q; Zhang R; Shi XD; Sun R; Chen J; Song Z; Jiang X; Shang L; Xiao G; Kong X; Liu C; Wong PP Nat Commun; 2023 Nov; 14(1):7033. PubMed ID: 37923799 [TBL] [Abstract][Full Text] [Related]
87. Bmi1 Maintains the Self-Renewal Property of Innate-like B Lymphocytes. Kobayashi M; Lin Y; Mishra A; Shelly C; Gao R; Reeh CW; Wang PZ; Xi R; Liu Y; Wenzel P; Ghosn E; Liu Y; Yoshimoto M J Immunol; 2020 Jun; 204(12):3262-3272. PubMed ID: 32332108 [TBL] [Abstract][Full Text] [Related]
88. Bmi1 is required for tumorigenesis in a mouse model of intestinal cancer. Maynard MA; Ferretti R; Hilgendorf KI; Perret C; Whyte P; Lees JA Oncogene; 2014 Jul; 33(28):3742-7. PubMed ID: 23955081 [TBL] [Abstract][Full Text] [Related]
89. The BMI1 inhibitor PTC-209 is a potential compound to halt cellular growth in biliary tract cancer cells. Mayr C; Wagner A; Loeffelberger M; Bruckner D; Jakab M; Berr F; Di Fazio P; Ocker M; Neureiter D; Pichler M; Kiesslich T Oncotarget; 2016 Jan; 7(1):745-58. PubMed ID: 26623561 [TBL] [Abstract][Full Text] [Related]
90. Redox-dependent BMI1 activity drives in vivo adult cardiac progenitor cell differentiation. Herrero D; Tomé M; Cañón S; Cruz FM; Carmona RM; Fuster E; Roche E; Bernad A Cell Death Differ; 2018 Mar; 25(4):809-822. PubMed ID: 29323265 [TBL] [Abstract][Full Text] [Related]
93. BMI1 in the heart: Novel functions beyond tumorigenesis. Yang D; Liu HQ; Yang Z; Fan D; Tang QZ EBioMedicine; 2021 Jan; 63():103193. PubMed ID: 33421944 [TBL] [Abstract][Full Text] [Related]
94. Combination of BMI1 and MAPK/ERK inhibitors is effective in medulloblastoma. Badodi S; Pomella N; Lim YM; Brandner S; Morrison G; Pollard SM; Zhang X; Zabet NR; Marino S Neuro Oncol; 2022 Aug; 24(8):1273-1285. PubMed ID: 35213723 [TBL] [Abstract][Full Text] [Related]
95. Identification of BMI1 promoter inhibitors from Streptomyces sp. IFM-11958. Yokoyama Y; Arai MA; Hara Y; Ishibashi M Bioorg Med Chem; 2019 Jul; 27(13):2998-3003. PubMed ID: 31079965 [TBL] [Abstract][Full Text] [Related]
97. Dysregulation of Bmi1 promotes malignant transformation of hepatic progenitor cells. Zhang R; Wu WR; Shi XD; Xu LB; Zhu MS; Zeng H; Liu C Oncogenesis; 2016 Feb; 5(2):e203. PubMed ID: 26926789 [TBL] [Abstract][Full Text] [Related]
98. EPS8 supports pancreatic cancer growth by inhibiting BMI1 mediated proteasomal degradation of ALDH7A1. Tan M; Meng J; Sun X; Fu X; Wang R Exp Cell Res; 2021 Oct; 407(1):112782. PubMed ID: 34391775 [TBL] [Abstract][Full Text] [Related]
99. BMI1 regulates multiple myeloma-associated macrophage's pro-myeloma functions. Zhang D; Huang J; Wang F; Ding H; Cui Y; Yang Y; Xu J; Luo H; Gao Y; Pan L; Wu Y; Gong Y; Xie L; Liu Z; Qu Y; Zhang L; Liu W; Zhang W; Zhao S; Yi Q; Niu T; Zheng Y Cell Death Dis; 2021 May; 12(5):495. PubMed ID: 33993198 [TBL] [Abstract][Full Text] [Related]
100. Expression and therapeutic targeting of BMI1 in canine gliomas. Al-Nadaf S; Peacott-Ricardos KS; Dickinson PJ; Rebhun RB; York D Vet Comp Oncol; 2022 Dec; 20(4):871-880. PubMed ID: 35833892 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]